Hsa-miR-665 Is a Promising Biomarker in Cancer Prognosis

Biomarkers are biomolecules used to identify or predict the presence of a specific disease or condition. They play an important role in early diagnosis and may be crucial for treatment. MicroRNAs (miRNAs), a group of small non-coding RNAs, are more and more regarded as promising biomarkers for sever...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-10, Vol.15 (20), p.4915
Main Authors: Guan, Xuefeng, Pavani, Krishna Chaitanya, Chunduru, Jayendra, Broeckx, Bart J. G, Van Soom, Ann, Peelman, Luc
Format: Article
Language:English
Subjects:
Apoptosis
B cells
Biomarkers
Bladder cancer
Breast cancer
Cancer
Development and progression
Developmental stages
Diagnosis
Diseases
Down-regulation
Drug resistance
Gene expression
Genetic engineering
Health savings accounts
Homeostasis
Kinases
Lung cancer
Medical prognosis
Medical research
Medical screening
Medicine, Experimental
MicroRNA
MicroRNAs
miRNA
Prognosis
Proteins
Relapse
Review
Tumors
Urine
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Biomarkers are biomolecules used to identify or predict the presence of a specific disease or condition. They play an important role in early diagnosis and may be crucial for treatment. MicroRNAs (miRNAs), a group of small non-coding RNAs, are more and more regarded as promising biomarkers for several reasons. Dysregulation of miRNAs has been linked with development of several diseases, including many different types of cancer, and abnormal levels can be present in early stages of tumor development. Because miRNAs are stable molecules secreted and freely circulating in blood and urine, they can be sampled with little or no invasion. Here, we present an overview of the current literature, focusing on the types of cancers for which dysregulation of miR-665 has been associated with disease progression, recurrence, and/or prognosis. It needs to be emphasized that the role of miR-665 sometimes seems ambiguous, in the sense that it can be upregulated in one cancer type and downregulated in another and can even change during the progression of the same cancer. Caution is thus needed before using miR-665 as a biomarker, and extrapolation between different cancer types is not advisable. Moreover, more detailed understanding of the different roles of miR-665 will help in determining its potential as a diagnostic and prognostic biomarker.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15204915